Rigel Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 51.45 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 961.08M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test;...